申请人:GLAXOSMITHKLINE LLC
公开号:WO2013096151A1
公开(公告)日:2013-06-27
The invention is directed to substituted quinoline derivatives. Specifically, the invention is directed to compounds according to Formula (I): wherein R1, R2, R3; R4; and R5 are defined herein. The compounds of the invention are inhibitors of lactate dehydrogenase A and can be useful in the treatment of cancer and diseases associated with tumor cell metabolism, such as cancer, and more specifically cancers of the breast, colon, prostate and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting lactate dehydrogenase A activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
该发明涉及取代喹啉衍生物。具体而言,该发明涉及符合以下式(I)的化合物:其中R1、R2、R3;R4;和R5在此处被定义。该发明的化合物是乳酸脱氢酶A的抑制剂,可用于治疗癌症和与肿瘤细胞代谢相关的疾病,如乳腺癌、结肠癌、前列腺癌和肺癌等。因此,该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物来抑制乳酸脱氢酶A活性和治疗相关疾病的方法。